Taiwan · Delayed Price · Currency is TWD Pell Bio-Med Technology Company Description
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products.
It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors.
The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-edited immune cell therapy.
The company was founded in 2017 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Cheng Long Lin |
Contact Details
Address: No. 87, Xinhu 2nd Rd. Taipei Taiwan | |
| Phone | 886 2 8791 1789 |
| Website | pellbmt.com |
Stock Details
| Ticker Symbol | 6949 |
| Exchange | Taiwan Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006949001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Cheng Long Lin | Founder, Chief Executive Officer, GM, Manager and Chairman |
| Chang-Min Wu | Financial Officer, Accounting Officer, Accounting Supervisor and Corporate Governance Officer |
| Jian Run Chen | Chief Human Resources Officer and Director |